Compounds useful for the treatment of diseases

1. A compound of formula (1 )

wherein the (CH2)_n-C(=0)Q¹ group is in meta or para position,

5 - R¹ and R² are independently selected from H and C^-C^ alkyl,

- n is 0,1 or 2, and,

- Q¹ is a group selected from:

*-NH-CrC₄alkyl, and a group *-N(R⁶)-Q²-A, wherein

10 - Q² is a single bond or a C1-C4 alkylene,

- R⁶ is H or CrC₄ alkyl,

- p is 1 or 2, and

- A is a C3-C10 cycloalkyl, 2 carbon atoms or more of said cycloalkyl being optionally bridged by one or more carbon atoms, preferably by 15 1, 2, 3 or 4 carbon atoms, O-phenyl-pyrazolyl, 5 to 10 membered heterocyclic group, optionally aromatic, comprising one, two, three or four heteroatoms selected from O, S or N, optionally substituted with C1-C4 alkyl or O-C1-C4 alkyl, or a group of formula

R³

R⁵

R⁵

- R³, R⁴, R⁵, R⁶ and R⁷ are the same or different and are selected from H, C1-C4 5 alkyl, OR⁹, SR⁹, SOR⁹, S0₂R⁹, halo, CN, CF₃, OCF₃, phenyl, O-phenyl, S-phenyl, S0₂-morpholinyl, 0-(CH₂)₃-pyrrolidinyl, COOR⁹, S0₂NR⁹R¹°, CONR⁹R¹⁰, NR⁹R¹⁰ and NHCOR¹⁰;

- R⁹ and R¹⁰ are the same or different and are selected from H or C1-C4 alkyl and the * represents the attachment point to the carbonyl group;

10 or, if appropriate, their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof,

with the proviso that when n is 0, then Q¹ is not -NHCH₃, and, when n is 1 or 2, then:

1 ) Q¹ is *-NH-CrC₄alkyl, or *-N(R⁸)-Q²-A where A is

15 - C₃-Cio cycloalkyl, 2 carbon atoms or more of said cycloalkyl being optionally bridged by one or more carbon atoms,

- O-phenyl-pyrazolyl,

- 5 to 10 membered heterocyclic group, optionally aromatic, comprinsing one, two, three or four heteroatoms selected from O, S 20 or N optionally substituted with C1-C4 alkyl or O-C1-C4 alkyl, said heterocyclic group being other than pyridyl,

a group of formula

R3

or ■' wherein one of R³ to R⁷ is CN, SOR⁹, S0₂R⁹, phenyl, O-phenyl, S-phenyl, S0₂-morpholinyl or 0-(CH₂)₃pyrrolidinyl, and/or,

2) when one of R¹ and R² is H, the other is not CH₃.

5 2. A compound according to claim 1 wherein Q¹ is a group of formula

or *-N(R⁸)-Q²-A, wherein Q* is a single bond or a C1-C4 alkylene, R° is H and A is

n2 ;,

10 wherein R³, R⁴ R⁵, R⁶ and R⁷ are as defined in claim 1.

3.A compound according to claims 1 or 2 wherein Q¹ is a group*-N(R⁸)-Q²-A wherein A is a group of formula

wherein R³, R⁴ R⁵, R⁶ and R⁷ are selected from H, C_rC₄ alkyl, OR⁹, SR⁹, Cl, F, CF3, OCF₃, COOR⁹, S0₂NR⁹R¹°, and at least 2 of R³ to R⁷ represent H,

wherein R⁹ and R¹⁰ are the same or different and are selected from H or C1-C4 5 alkyl.

4. A compound according to claim 3 wherein R³, R⁴ R⁵, R⁶ and R⁷ are the same or different and are selected from H, CH₃, OH, OCH₃, SCH3, OCH₂CH₃, Cl, F, CF3, OCF3, COOH, S0₂NH₂, and at least 2 of R³ to R⁷ represent H.

5. A compound according to claim 4 wherein R³, R⁴ R⁵, R⁶ and R⁷ are the same 10 or different and are selected from H, CH3, OH, OCH3, SCH3, OCH₂CH₃, Cl, F, CF3, OCF₃, COOH, S0₂NH₂, and at least 3 of R³ to R⁷ represent H.

6. A compound according to claim 1 wherein Q¹ is *-N(R⁸)-Q²-A where A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or adamantyl.

7. A compound according to any one of claims 1 to 6 wherein R⁸ is H, methyl or 15 ethyl.

8. A compound according to any one of claims 1 to 7 wherein Q² is selected from a bond, -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -C(CH₃)₂-CH₂-, -CH₂-C(CH₃)2-, and CH(CH₃)-.

20 9. A compound according to claim 1 or 2 wherein Q¹ is

10. A compound according to any one of claims 1 to 9 wherein n is 0 or 1.

11. A compound according to any one of claims 1 to 10 wherein R¹ is H and R² is H or CH₂CH₃.

5 12. A compound according to any one of claims 1 to 10 wherein R¹ is CH3 and R² is CH₃.

13. The (R,R)-stereoisomer of a compound according to any one of claims 1 to 12.

14. A compound according to any one of claims 1 to 13 wherein the (CH₂)_n10 C(=0)Q¹ group is in position meta.

15. A compound according to claim 1 selected from the group consisting of Λ/-cycloheptyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3- (hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cyclohexylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

15 (hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}-Λ/-methylacetamide;

Λ/-[(1S)-1-cyclohexylethyl]-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}-Λ/-isopropylacetamide;

20 Λ/-cyclopentyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cyclobutylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cyclopentylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

25 (hydroxymethyl)phenyl]ethyl}amino)propy!]pheny!}acetamide;

Λ/-cyclohexyl-2-{3-[(2R)-2-({(2R)-2-hydiOxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}aceΐamide;

Λ/-cyclobutyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cyclohexylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydiOxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cyclopropylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(cycloheptylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-31(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(1-adamantylmethyl)-2-{3-[(2R)-2-({(2R)-2-hydrc>xy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

1Λ/-2-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(2-cyclohexylethyl)-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phΘnyl}-Λ/-methylacetamide;

Λ/-cycloheptyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}-Λ/-methylacetamide;

Λ/-cyclohexyl-Λ/-ethyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(2-cyclohexylethyl)-2-{3-[(2R)-2-({(2R)-2-hydrc>xy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide;

Λ/-(4-chlorobenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-(2,6-dimethoxybenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-benzyl-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

4-{(1R)-2-[(2-{3-[2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]phenyl}-1,1N-[2-fluoro-5-(trifluoromethyl)benzyl]-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3- (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-(2,6-dichlorobenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

5 2-{3-[2-({(2/?)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2 methylpropyl]phenyl}-Λ/-[2-(methylthio)benzyl]acetamide;

Λ/-(2,3-dimethylbenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

2-{3-[2-({(2/?)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2 10 methylpropyl]phenyl}-Λ/-[3-(trifluoromethyl)benzyl]acetamide;

Λ/-[4-chloro-3-(trifluoromethyl)benzyl]-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-[2-chloro-5-(trifluoromethyl)benzyl]-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

15 Λ/-[3,5-bis(trifluoromethyl)benzyl]-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-[3-fluoro-5-(trifluoromethyl)benzyl]-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

Λ/-[2-(4-chlorophenyl)ethyl]-3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxy-

20 methylphenyl)ethylamino]-2-methylpropyl}benzamide;

3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-2-methylpropyl}-Λ/-[2-(4-methylphenyl)ethyl]benzamide;

3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-2-methyl-propyl}-Λ/-[2-(4-trifluoromethylphenyl)ethyl]benzamide;

25 /V-[2-(3,4-dichlorophenyl)ethyl]-3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]-2-methyl-propyl}-bΘnzamide;

Λ/-[2-(3,4-dimethylphenyl)ethyl]-3-{2-[(2/?)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-2-methylpropyl}benzamide;

3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)ethylamino]-230 methyl-propyl}-/V-(2-naphthalen-2-yl-ethyl)benzamide;

Λ/-(1,1-dimethyl-2-phenylethyl)-3-{2-[(2/?)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-2-methylpropyl}benzamide;

3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino]-2-methylpropyl}-Λ/-(2-methyl-2-phenylpropyl)benzamide;

Λ/-(4-chlorobenzyl)-3-{2-[(2/?)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]-2-methylpropyl}benzamide;

A/-(2,6-dimethoxybenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)ethyl]phenyl}acetamide;

Λ/-(3,4-dichlorobenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)ethyl]phenyl}acetamide;

Λ/-benzyl-2-{3-[2-({(2/?)-2-hydroxy-2-[4-hydroxy-31(hydroxymethyl)phenyl]ethyl}amino)ethyl]phenyl}acΘtamide;

Λ/-(2,3-dihydro-1H-inden-2-yl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)ethyl]phenyl}acetamide;

2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)ethyl]phenyl}-Λ/-(2-pheπylethyl)acetamide;

12-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymΘthyl)phenyl]ethyl}amino)ethyl]phenyl}-Λ/-(3-phenylpropyl)acetamide;

Λ/-benzyl-3-[(2R)-2-({(2/?)-2-hydroxy-2-[4-hydroxy-3(hydroxymΘthyl)phenyl]ethyl}amino)propyl]benzamide;

Λ/-(3,4-dichlorobeπzyl)-3-[(2/?)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzaπnide;

Λ/-[2-fluoro-5-(trifluoromethyl)benzyl]-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

Λ/-(2,6-dimethoxybenzyl)-3-[(2ft)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

Λ/-[2-(4-chlorophenyl)ethyl]-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

Λ/-(2,3-dihydro-1H-inden-2-yl)-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

3-[(2H)-2-({(2/?)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]-Λ/-(2-phenylethyl)benzamide;

3-[(2/?)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

3-[(2 R)-2-({(2 R)-2-hyd roxy-2-[4-hyd roxy-3(hydroxymethyl)ρhenyl]ethyl}amino)propyl]-Λ/-(3-phenylpropyl)benzamide;

4-[(1 R)-2-({(1 R)-2-[3-(3,4-dihydroisoquinolin-2(1 H)-ylcarbonyl)phenyl]-1-methylethyl}amino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol;

Λ/-(2,3-dimethylbenzyl)-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

N-(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amiπo)propyl]benzamide;

Λ/-(4-chlorobenzyl)-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-31(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]-Λ/-phenylbenzamide;

Λ/-[4-(aminosulfonyl)benzyl]-3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)propyl]benzamide;

N-[2-(3-Fluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymθthyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(2-pyrrolidin-1-ylethyl)benzamide;

N-[2-(2,6-dichlorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamidθ;

N-(2,3-dihydro-1H-iπden-2-ylmethyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-(2-{4-[(butylaπ∩ino)carbonyl]phenyl}ethyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[2-(phenylthio)phenyl]ethyl}benzainide;

N-(2-cyclohexylethyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(3-phenylpropyl)benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(2-phenylethyl)benzamide;

N-[2-(3,6-dichloro-2-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(3-methoxyphenyl)ethyl]benzamide;

N-[2-(3-ethoxyphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)pheπyl]ethyl}amino)-21methylpropyl]-N-{2-[4-(3-pyrrolidin-1 -ylpropoxy)phenyl]ethyl}benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[2-(3-pyrrolidin-1-ylpropoxy)phenyl]ethyl}benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}annino)-2-methylpropyl]-N-{2-[3-(3-pyrrolidin-1-ylpropoxy)phenyl]ethyl}benzamide;

N-[2-(4-Chlorophenyl)ethyl]-N-ethyl-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzainide;

2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl] ethyl}amino)-2-methylpropyl]phenyl}-N-(3-pyrrolidin-1-ylpropyl)acetamide;

N-(Cycloheptylmethyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetamide;

N-1-Adamantyl-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}acetannide;

N-Benzyl-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl) phenyl]ethyl}amino)-2-methylpropyl]phenyl}-N-methylacetamide;

N-[2-(4-Fluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(4-phenoxyphenyl)ethyl]benzamide;

N-[2-(4-ethoxyphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(4-ethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3'(hydroxymethyl)phenyl]ethyl}amino)-2- methylpropyl]-N-[2-(6-methylpyridin-2-yl)ethyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amiπo)-2-methylpropyl]-N-[2-(2-methoxyphenyl)ethyl]benzamide;

5 methyl 4-[({3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)-2-methylpropyl]benzoyl}amino)methyl]benzoate;

N-[4-(dimethylamino)benzyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-{2-[3-fluoro-4-(trifluoromethyl)phenyl]ethyl}-3-[2-({(2R)-2-hydroxy-2-[4-

10 hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(3-fluoro-4-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(2,3-difluoro-4-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

15 3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(2-mesitylethyl)benzamide;

N-[2-(2_I6-difluoro-3-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(6-chloro-2-fluoro-3-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-

20 hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(2-chloro-6-fluoro-3-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(5-fluoro-2-methylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

25 N-{2-[3-fluoro-5-(trifluoromethyl)phenyl]ethyl}-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[2-(trifluoromethyl)phenyl]ethyl}bΘnzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-230 methylpropyl]-N-[2-(2,4,5-trimethylphenyl)ethyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(2-pyridin-2-ylethyl)benzamide;

N-[2-(1H-benzimidazol-2-yl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[4-(morpholin-4-ylsulfonyl)phenyl]ethyl}benzamide;

5 N-[2-(3-chloro-2-hydroxyphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[4-fluoro-2-(trifluoromethyl)benzyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-(3-chlorobenzyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

10 (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-(2-chlorobenzyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(4,6-dimethylpyrimidin-2-yl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

15 3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(3-methylpyridin-2-yl)ethyl]benzamide;

N-[2-(2-chlorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(1-adamantyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

20 (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(1-naphthyl )ethyl]benzamide;

N-[2-(2,6-dimethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

25 3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}annino)-2-methylpropyl]-N-{2-[4-(methylthio)phenyl]ethyl}benzamide;

N-[2-(5-chloro-2-fluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(2-chloro-4-fluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-330 (hydroxymethyl)phenyl]ethyl}amino)-2-n∩ethylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}annino)-2-N-[2-(2,3-dichlorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3- (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(4-methoxy-2,3-dimethylphenyl)ethyl]benzamide;

5 N-(2-biphenyl-4-ylethyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phΘnyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(2_I4-dimethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(2,3-dimethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

10 (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamidθ;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzamide;

N-[2-(4-chloro-2-fluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

15 N-(2,5-dimethylbenzyl)-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-(3,4-Dichlorobenzyl)-3-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}propanamide;

3-[2-({(2R)-2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-220 methylpropyl]-N-{2-[4-(trifluoromethoxy)phenyl]ethyl}benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(4-hydroxyphenyl)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(4-hydroxy-3-methylphenyl)ethyl]benzamide;

25 N-[2-(4-hydroxy-2,3-dimethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3 (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-[2-(4-hydroxy-2,5-dimethylphenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3 (hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

N-(3,4-dichlorobenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-

30 (hydroxymethyl)phenyl]ethyl}amino)-2-mθthylpropyl]phenyl}acetamide;

N-(3,5-dichlorobenzyl)-2-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-32-{3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]phenyl}-N-(pyridin-2-ylmethyl)acetamide;

N-ethyl-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl} amino)-2-methylpropyl]-N-(3-phenylpropyl)benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[3-(4-hydroxyphenyl)propyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[2-(3-methylphenyl)ethyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]℮thyl}amino)-21methylpropyl]-N-[2-(6-methoxypyridin-3-yl)ethyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-[3-(3-methoxyphenyl)propyl]benzamide;

N-[3-(4-Chlorophenyl)propyl]-3-{2-[(2R)-2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]-2-methylpropyl}benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-{2-[4-(1H-pyrazol-1-yl)phenoxy]ethyl}benzamide;

N-[2-(3,4-difluorophenyl)ethyl]-3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide;

3-[2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]-N-(2-quinolin-5-ylethyl)benzamide; and, N-[3-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)propyl]-3-[2-({(2R)-2-hydroxy-2-[4- hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)-2-methylpropyl]benzamide.

16.A process for the preparation of a compound of formula (1) as described in any one of claims 1 to 15 or a pharmaceutically acceptable salt or derived form thereof comprising the step of coupling an acid of formula (2):

(2)

HO'

HO'

with an amine of formula N(R⁸)-Q²-A (3),

wherein R⁸, Q², A, p and R³ to R⁶ are as previously defined for compounds of formula (1).

5 17. A pharmaceutical composition comprising at least an effective amount of a compound of the formula (1) as described in any one of claims 1 to 15 or a pharmaceutically acceptable salt or derived form thereof.

18.A pharmaceutical composition according to any one of claims 1 to 15, further comprising one or more pharmaceutically acceptable excipients and/or 10 additives.

19.A compound of formula (1) as described in any one of claims 1 to 15 or a pharmaceutically acceptable salt, derived form or composition thereof, for use as a medicament.

20.A compound of formula (1) as described in any one of claims 1 to 15 or a 15 pharmaceutically acceptable salt, derived form or composition thereof, for use in the treatment of diseases, disorders, and conditions in which the β2 receptor is involved.

21.A compound of formula (1) as described in any one of claims 1 to 15 or a pharmaceutically acceptable salt, derived form or composition thereof, for use 20 in the treatment of diseases, disorders, and conditions selected from the group consisting of :

• asthma of whatever type, etiology, or pathogenesis, in particular asthma that is a member selected from the group consisting of atopic asthma, non-atopic asthma, allergic asthma, atopic bronchial IgE-mediated asthma, bronchial asthma, essential asthma, true asthma, intrinsic asthma caused by pathophysiologic disturbances, extrinsic asthma caused by environmental factors, essential asthma of unknown or inapparent cause, non-atopic asthma, bronchitic asthma, emphysematous asthma, exercise-induced asthma, allergen induced asthma, cold air induced asthma, occupational asthma, infective asthma caused by bacterial, fungal, protozoal, or viral infection, non-allergic asthma, incipient asthma, wheezy infant syndrome and bronchiolytis,

10 chronic or acute bronchoconstriction, chronic bronchitis, small airways obstruction, and emphysema,

obstructive or inflammatory airways diseases of whatever type, etiology, or pathogenesis, in particular an obstructive or inflammatory airways disease that is a member selected from the group consisting of chronic 15 eosinophilic pneumonia, chronic obstructive pulmonary disease (COPD), COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated or not associated with COPD, COPD that is characterized by irreversible, progressive airways obstruction, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper20 reactivity consequent to other drug therapy and airways disease that is associated with pulmonary hypertension,

bronchitis of whatever type, etiology, or pathogenesis, in particular bronchitis that is a member selected from the group consisting of acute bronchitis, acute laryngotracheal bronchitis, arachidic bronchitis, 25 catarrhal bronchitis, croupus bronchitis, dry bronchitis, infectious asthmatic bronchitis, productive bronchitis, staphylococcus or streptococcal bronchitis and vesicular bronchitis,

acute lung injury,

• bronchiectasis of whatever type, etiology, or pathogenesis, in particular bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis, sacculated bronchiectasis, fusiform bronchiectasis, capillary bronchiectasis, cystic bronchiectasis, dry 5 bronchiectasis and follicular bronchiectasis.

22. The use of a compound of formula (1) as described in any one of claims 1 to 15 or of a pharmaceutically acceptable salt, derived form or composition thereof, for the manufacture of a drug having a β2 agonist activity.

23. The use of a compound of formula (1) as described in any one of claims 1 10 to 15 or of a pharmaceutically acceptable salt, solvate or composition thereof, for the manufacture of a drug for the treatment of diseases, disorders, and conditions selected from the group as described in claim 21.

24. A method of treatment of a mammal, including a human being, with a β2 agonist including treating said mammal with an effective amount of a compound 15 of formula (1) as described in any one of claims 1 to 15 or with a pharmaceutically acceptable salt, derived form or composition thereof.

25. A method according to claim 24 where the disease, disorder or condition is selected from the group as described in claim 21.

26. A combination of a compound according to any one of claims 1 to 15 with a 20 therapeutic agent selected from:

(a) 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists,

(b) Leukotriene antagonists (LTRAs) including antagonists of LTB₄, LTC₄, LTD₄, and LTE₄,

25 (c) Histamine receptor antagonists including H1 and H3 antagonists,

(d)αr and α₂-adrenoceptor agonist vasoconstrictor sympathomimetic agents for decongestant use,

(e) muscarinic M3 receptor antagonists or anticholinergic agents,

(f) PDE inhibitors, e.g. PDE3, PDE4 and PDE5 inhibitors,

(g) Theophylline,

(h) Sodium cromoglycate,

(i) COX inhibitors both non-selective and selective COX-1 or COX-2 inhibitors (NSAIDs),

(j) Oral and inhaled glucocorticosteroids, such as DAGR (dissociated agonists of the corticoid receptor)

(k) Monoclonal antibodies active against endogenous inflammatory entities,

(l) Anti-tumor necrosis factor (anti-TNF-α) agents,

(m)Adhesion molecule inhibitors including VLA-4 antagonists,

1(n) Kinin-Bi - and B₂ -receptor antagonists,

(o) Immunosuppressive agents,

(p) Inhibitors of matrix metalloproteases (MMPs),

(q) Tachykinin NK·i, NK₂ and NK₃ receptor antagonists,

(r) Elastase inhibitors,

1(s) Adenosine A2a receptor agonists,

(t) Inhibitors of urokinase,

(u) Compounds that act on dopamine receptors, e.g. D2 agonists,

(v) Modulators of the NFicβ pathway, e.g. IKK inhibitors,

(w) modulators of cytokine signalling pathways such as p38 MAP kinase, syk kinase or JAK kinase inhibitor,

(x) Agents that can be classed as mucolytics or anti-tussive,

(y) Antibiotics,

(z) HDAC inhibitors, and,

(aa) PI3 kinase inhibitors.